Search results
Added:
11 months ago
ESC HF 25 - Safety outcomes from PRAISE-HFrEF show that glucagon-like peptide-1 receptor agonism (GLP-1 RA) treatment for heart failure with reduced ejection fraction (HFrEF) and obesity was not associated with increased risk of heart failure hospitalisation or mortality compared to placebo, with greater benefits observed in patients with higher BMI.Dr Varun Sundaram (Case Western Reserve…
View more
Added:
1 year ago
HFA 24 - We are joined by Dr Muthiah Vaduganathan (Brigham and Women’s Hospital, US) to discuss the design and baseline characteristics of the FINE-HEART(Bayer) integrated pooled analysis of finerenone, an on-steroidal mineralocorticoid receptor (MRA) antagonist, in over 19000 patients with heart failure and CKD.FINE-HEART includes patients with type 2 diabetes, chronic kidney disease and/or…
View more
Added:
1 year ago
HFA 24 - Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) joined onsite by Dr Jasper Brugts (Erasmus University Medical Centre, NL) to discuss the first results from the TITRATE-HF study.TITRATE-HF is a real-world multicenter longitudinal study which aims to assess drug sequencing strategies for guideline-directed medical therapy (GDMT) initiation in patients with de novo,…
View more
Added:
11 months ago
ESC HF 25 - Real-world findings suggest kidney function decline could precede heart failure events by up to a year.Prof Nicolas Girerd (University Hospital of Nancy, Nancy, FR) discusses real-world findings from pooled trials EPHESUS, EMPHASIS-HF and BARCELONA. The study investigated if longitudinal changes in kidney function could help identify patients with HFrEF at a higher risk of…
View more
Added:
1 year ago
HFA 2024 — Join experts, Dr Harriette Van Spall (McMaster University, CA) and Dr Mark Petrie (University of Glasgow, UK) for an insightful wrap up of the novel data presented at 2024's Heart Failure Congress.00:24 - STEP HFpEF Programme: Semaglutide 2.4 mg and NTproBNP in obesity-related HFpEF & Semaglutide therapy and diuretic use in obesity-related HFpEF02:20 - EMPACT-MI: The effect of…
View more
Added:
1 year ago
In this Meet the Experts session, from e-SPACE Heart Failure 2024, Prof Shelley Zieroth, Dr Shahzeb Khan and Prof Gianluigi Savarese examine the clinical impact of hyperkalemia in heart failure and discuss strategies for its long-term management.
View more
Added:
1 year ago
EASD 24 - We are joined by Professor John McMurray (University of Glasgow, UK) to discuss the key findings from a diabetes subgroup analysis of the FINEARTS-HF study.Interview Questions:1. What is the reasoning behind this analysis?2. What was the study design and patient cohort?3. What are the key findings?4. In your opinion, what can explain this risk reduction?5. What are the take-home…
View more
Added:
11 months ago
ESC HF 25 - FIVE-STAR primary outcome is neutral, though finerenone was shown to significantly reduce UACR rates with a 29% greater reduction compared to placebo.We are joined by Dr Atsushi Tanaka (Saga University, Saga, JP) to discuss the findings from FIVE-STAR, a randomized trial investigating the effects of finerenone on vascular stiffness and cardiorenal biomarkers in patients with type 2…
View more
Added:
1 year ago
AHA Conference 2024 — REALIZE-K: Impact of sodium zirconium cyclosilicate (SZC) on HFrEF patient's potassium levels whilst on spironolactone.Late-Breaker Host, Dr Harriette Van Spall (McMaster University, CA) is joined onsite by Dr Mikhail Kosiborod (Saint Luke's Mid America Heart Institute, US) to discuss the findings from the REALIZE-K Study (NCT04676646; AstraZeneca).REALIZE-K is a phase 4…
View more
Added:
1 year ago
ESC 2024 - We are joined by Dr Muthiah Vaduganathan (Brigham and Women’s Hospital and Harvard Medical School, US) for a concise and insightful summary of the hot-line and late-breaking data that is expected to have an impact on heart failure care.Trials covered in detail include:FINEARTS HFHELIOS-BRESHAPE-HF2Recorded on-site at ESC Congress 2024, London.Editors: Jordan Rance and Mirjam Boros…
View more